IgA nephropathy (IgAN), also known as Berger's disease, is a B-cell-mediated kidney disease where abnormal immune complexes accumulate in the kidneys, causing damage to the glomeruli (small filters inside the kidneys).
It is estimated that there are about 150,000 to 200,000 people in the United States with IgAN. At least 50% of IgAN patients progress to end-stage kidney disease within 20 years, requiring dialysis or a kidney transplant. Calliditas Therapeutics' Tarpeyo, Travere Therapeutics' Filspari, Otsuka's Voyxact, and Novartis' Fabhalta and Vanrafia are some of the FDA-approved therapies for IgA nephropathy.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
by Prabha Kurup
For comments and feedback: contact editorial@rttnews.com